Abstract
Flexibilities for sample size allocation are often demanded for achieving multiple study objectives in combination drug trials. The global tests of Hung, Chi and Lipicky are extended for analysis of unbalanced factorial design trials to test the hypothesis that at least one of the non-zero dose combinations of two drugs is more effective than the respective component doses. When the dose combinations have heterogeneous effect sizes, an unbalanced design may induce greater power than the balanced design. An adjusted p-value approach is proposed for testing the individual dose combinations under the condition that the maximum type I error probability is protected.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
